Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other traditional risk factors, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Structure’s oral GLP-1 a ‘work in progress’ following Phase IIa obesity and diabetes data
Phase IIa data for Structure Therapeutics’ oral GLP-1 drug candidate for type 2 diabetes and obesity bested analyst expectations on safety and tolerability, but lower-than-hoped-for
December 19, 2023